Bravinton

General characteristics. Structure:

Active ingredient: 5 mg of a Vinpocetine in 1 ml of solution.

Excipients: benzyl alcohol, sodium sulfite, sorbitol, tartaric acid, water for an injection.

Pharmacological properties:

Pharmacodynamics. Bravinton selectively improves a blood stream in a brain and portability of cerebral ischemia. The mechanism is caused by direct spazmolitichny myotropic action on brain vessels. Strengthens a regional blood stream in an ishemizovaniye to a brain zone, causes insignificant lowering of arterial pressure. The Vinpocetine improves microcirculation in brain tissues, slows down aggregation of thrombocytes, reduces viscosity of blood.

Increases resistance of cells of a brain to a hypoxia, strengthens aerobic process of utilization of glucose. Stimulates also anaerobic metabolism of glucose in way braking of phosphodiesterase and stimulation of adenylatecyclase that leads to accumulation in cells of a brain of cyclic AMF. Raises contents of catecholamines in a brain.

Pharmacokinetics. At parenteral administration the volume of distribution reaches 5,3 l/kg.

Indications to use:

- acute and chronic insufficiency of cerebral circulation;

- for decrease in mental and neurologic symptoms of cerebral insufficiency (memory disturbance, dizziness, the main pain, disturbances of the movement);

- at atherosclerotic and angiospastichny changes of mesh and vascular covers of an eye, at degenerative changes of a macula lutea, at secondary glaucoma, with partial fibrinferments of vessels;

- at decrease in hearing of a vascular or toxic origin, Menyer's disease, a sonitus.

Route of administration and doses:

Bravinton solution to infusions of 0,5% is applied only in slow drop infusion. An initial daily dose for adults - 20 mg (contents of 2 ampoules are dissolved in 500-1000 ml of infusion solution). Further the daily dose makes 30 mg (contents of 3 ampoules in 500-1000 ml of infusion solution). If necessary and satisfactory portability of drug the daily dose at careful increase entered intravenously for the tenth day can reach 1 mg/kg of body weight.

Treatment is continued by 10-14 days, gradually reducing a dose before drug withdrawal. After improvement of a clinical picture pass to administration of drug inside (tablets).

Features of use:

At a hemorrhagic cerebral stroke parenteral use of drug is possible only after disappearance of acute manifestations (in 5-7 days).

Side effects:

Perhaps insignificant lowering of arterial pressure, tachycardia, seldom premature ventricular contraction.

Interaction with other medicines:

The increased risk of bleedings against the background of parenteral administration of heparin.

Contraindications:

Heavy course of coronary heart disease, arrhythmia, periods of pregnancy and feeding by a breast.

Overdose:

In case of overdose (a lowering of arterial pressure, disturbance of a rhythm) of treatment symptomatic.

Storage conditions:

Drug should be kept in dry, protected from light and the place, unavailable to children, at the room temperature. A period of storage - 2 years.

Issue conditions:

According to the recipe

Packaging:

In ampoules on 2 ml, in a blister strip packaging of 5 ampoules, in a cardboard pack 2 packagings.